This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Nov;64(11):1841.

doi: 10.2967/jnumed.123.266101. Epub 2023 Sep 14.

HER2-Low Breast Cancer Can Be Visualized by HER2 PET

Renske Altena, Siri Af Burén, Thuy Tran, Rimma Axelsson

PMID: 37709535
DOI: 10.2967/jnumed.123.266101

Free article

Comment

HER2-Low Breast Cancer Can Be Visualized by HER2 PET

Renske Altena et al. J Nucl Med. 2023 Nov.

Free article

. 2023 Nov;64(11):1841.

doi: 10.2967/jnumed.123.266101. Epub 2023 Sep 14.

Authors

Renske Altena, Siri Af Burén, Thuy Tran, Rimma Axelsson

PMID: 37709535
DOI: 10.2967/jnumed.123.266101

No abstract available

PubMed Disclaimer

Comment in

Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
Seban RD. Seban RD. J Nucl Med. 2023 Nov;64(11):1841-1842. doi: 10.2967/jnumed.123.266490. Epub 2023 Sep 14. J Nucl Med. 2023. PMID: 37709533 No abstract available.

Comment on

Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients.
Seban RD, Champion L, Bellesoeur A, Vincent-Salomon A, Bidard FC. Seban RD, et al. J Nucl Med. 2023 Jul;64(7):1164-1165. doi: 10.2967/jnumed.123.265434. Epub 2023 May 25. J Nucl Med. 2023. PMID: 37230529 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal